About Contact Us Careers

-2 Market Analysis

Request Free Sample Copy

Report ID: 2702
Published Date: Dec 23, 2024
Report Format: PDF, PPT

Buy Now

-2 Market Analysis

The market is segmented by treatment into surgery, additional therapy, drugs, and others, out of which, the surgery segment is anticipated to hold the notable share in the global congenital anomalies treatment market over the forecast period owing to the high success rate of surgeries. Moreover, surgeries guarantee permanent cure for congenital heart disease, cleft palate, and other disorders, which is estimated to boost the segment growth.

Our in-depth analysis of the global market includes the following segments:

Type

Congenital Heart Disease
Down Syndrome
Cleft Lip and Cleft Palate
Club Foot
Phenylketonuria
Edward’s Syndrome
Others

Technology

Surgery
Additional Therapy
Drugs
Others

End-User

Hospitals
Specialty Clinics
Others

Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:

Congenital Anomalies Treatment Market Size & Share, Forecast Report 2037

Author Credits: Radhika Pawar

Report ID: 2702
Published Date: Dec 23, 2024
Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of congenital anomalies treatment is assessed at USD 172.27 million.

Congenital Anomalies Treatment Market size was over USD 165.79 million in 2024 and is projected to reach USD 297.49 million by 2037, witnessing around 4.6% CAGR during the forecast period i.e., between 2025-2037.

Asia Pacific industry is predicted to account for largest revenue share by 2037, on the back of advancements in the healthcare sector, and rising healthcare expenditure across the region.

The major players in the market are GlaxoSmithKline plc, Regeneron Pharmaceuticals, Inc., BioMarin Pharmaceutical Inc., Amgen Inc., Alexion Pharmaceuticals, Inc., Merck KGaA, Novartis International AG, Ipsen Pharma, Fresenius Kabi USA, and others.

Inquiry Before Buying Request Free Sample